SCREEN is involved in the development and sale of imaging systems that enable label-free capture and analysis of cell cultures and tissue samples. These systems incorporate a combination of cutting-edge artificial intelligence (AI) and our own independently developed optical technologies.
The SCREEN Group’s Vision
We hope to contribute to our customers’ ability to create well-made products. With this in mind, we have continued to fully develop our core technologies* and sought to actively utilize open innovation to provide new solutions that support our customers’ manufacturing capabilities.
This also connects to our goal of becoming an enterprise that can contribute to society on a global scale. As we move forward, the SCREEN Group will remain committed to using our business activities to resolve the many challenges facing society and to creating a sustainable future.
* Surface processing, direct imaging and image processing
Life Sciences Field
Biotechnology continues to make remarkable progress worldwide supported by advances in the research device and academic fields. Drug development and regenerative medicine based on discoveries such as iPS and ES cells have become mainstream, promising to significantly enhance everyone’s quality of life.
In the pharmaceutical industry, efforts to improve the readability of information shown on tablets are progressing, with the aim of preventing misidentification of medicines and accidental ingestion. The SCREEN Group will continue to utilize our proprietary image processing and direct imaging technologies to develop new equipment and support the growth of this important field.
We are also involved in the development and sale of specialized inkjet presses for tablet printing. These units enable non-contact, double-sided printing and inspection as well as visual inspection of tablets before printing.